Stabilitech
London, England, United Kingdom
About Stabilitech
Stabilitech is a privately held company focused on stabilisation of sensitive biological molecules, such as vaccines and biopharmaceuticals. The company was founded by Dr Jeff Drew, and started research operations in 2004. Stabilitech is based at the London Bioscience Innovation Centre, London UK. Stabilitech's goal is to improve the stability of vaccines and biopharmaceuticals using their proprietary formulation technology. Stabilitech's technology permits the long-term stabilisation of a wide range of thermally sensitive viruses, vaccines and biopharmaceuticals. Excipient compositions contain only chemical ingredients already used in clinical settings, approved injectables or on the Generally Regarded As Safe (GRAS) list. Their business model is to establish partnerships with major pharmaceutical and biotechnology companies, as well as with global health organisations, to commercialise their technology.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $10K – $50K
- Total funding: $11.6M
- Funding stage: Late Stage Venture
- Last round: Series C (Aug 2011)
- Website: stabilitech.com
- Phone: 44 2075 946146
Industries & Categories
Biotechnology, Commercial, Pharmaceutical
Canonical: https://fsome.com/organization/stabilitech-2612958 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.